Company ORIENT BIO Inc.

Equities

A002630

KR7002630002

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
526 ^KRW	-0.75%		+1.15%	-13.34%

2022	Pregen Inc. announced that it has received KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD.	CI
2022	Pregen Inc. announced that it expects to receive KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD. and other investors	CI

ORIENT BIO Inc. is a Korea-based company engaged in the biotechnology area. The Company produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. It also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.

Number of employees: 125

KRW in Million	2022	Weight	2023	Weight	Delta
Laboratory Animals Product 58.6 %	-	-	16,891	58.6 %	-
Laboratory Animals Merchandise 40.1 %	-	-	11,566	40.1 %	-
Other 1.3 %	-	-	362	1.3 %	-

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 99.4 %	26,194	99.7 %	28,651	99.4 %	+9.38%
Foreign 0.6 %	82	0.3 %	168	0.6 %	+104.14%

Managers	Title	Age	Since
Jae-Jin Jang CEO	Chief Executive Officer	63	-
Tae-Seok Han PRN	Corporate Officer/Principal	47	-
Sang-Nyeon Kim PRN	Corporate Officer/Principal	64	-
Joo-Min Kim PRN	Corporate Officer/Principal	60	01/01/01
Jae-Gu Choi AUD	Comptroller/Controller/Auditor	65	-

Members of the board	Title	Age	Since
Jae-Jin Jang CEO	Chief Executive Officer	63	-
Sook-Jong Choi BRD	Director/Board Member	59	-
Kang-Moon Choi BRD	Director/Board Member	56	-
Yong-Suk Cho BRD	Director/Board Member	66	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	118,583,005	76,347,398 ( 64.38 %)	14,879 ( 0.0125 %)	64.38 %

Name	Equities	%	Valuation
Orient Inc. 23.99 %	28,448,457	23.99 %	11 M ₩
ORIENT PRECISION INDUSTRIES INC 8.085 %	9,587,060	8.085 %	4 M ₩
Sook-Jong Choi 2.774 %	3,289,435	2.774 %	1 M ₩
Jae-Jin Jang 0.7554 %	895,776	0.7554 %	338 326 ₩
ORIENT BIO INC. 0.0125 %	14,879	0.0125 %	5 620 ₩

Name	Equities	%	Valuation
ORIENT BIO INC. 0.01%	14,879	0.01%	5,620 $

ORIENTBIO, Inc.

322 Galmachi-ro Jungwon-gu

13201, Seongnam-si

http://www.orientbio.co.kr

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ORIENT BIO INC.	-13.34%	4.56Cr
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.23%	11TCr
ARGENX SE	-0.38%	2.19TCr
BIONTECH SE	-12.15%	2.23TCr
GENMAB A/S	-7.66%	1.86TCr
WUXI APPTEC CO., LTD.	-36.52%	1.81TCr
BEIGENE, LTD.	-10.09%	1.7TCr
NEUROCRINE BIOSCIENCES, INC.	+3.33%	1.37TCr
SAREPTA THERAPEUTICS, INC.	+36.58%	1.24TCr

Bio Therapeutic Drugs